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BACKGROUND
Endovenous laser ablation and ultrasound-guided foam sclerotherapy are recom-
mended alternatives to surgery for the treatment of primary varicose veins, but their 
long-term comparative effectiveness remains uncertain.
METHODS
In a randomized, controlled trial involving 798 participants with primary varicose 
veins at 11 centers in the United Kingdom, we compared the outcomes of laser 
ablation, foam sclerotherapy, and surgery. Primary outcomes at 5 years were dis-
ease-specific quality of life and generic quality of life, as well as cost-effectiveness 
based on models of expected costs and quality-adjusted life-years (QALYs) gained 
that used data on participants’ treatment costs and scores on the EuroQol EQ-5D 
questionnaire.
RESULTS
Quality-of-life questionnaires were completed by 595 (75%) of the 798 trial partici-
pants. After adjustment for baseline scores and other covariates, scores on the Aber-
deen Varicose Vein Questionnaire (on which scores range from 0 to 100, with lower 
scores indicating a better quality of life) were lower among patients who underwent 
laser ablation or surgery than among those who underwent foam sclerotherapy (ef-
fect size [adjusted differences between groups] for laser ablation vs. foam sclero-
therapy, −2.86; 95% confidence interval [CI], −4.49 to −1.22; P<0.001; and for surgery 
vs. foam sclerotherapy, −2.60; 95% CI, −3.99 to −1.22; P<0.001). Generic quality-of-
life measures did not differ among treatment groups. At a threshold willingness-to-
pay ratio of £20,000 ($28,433 in U.S. dollars) per QALY, 77.2% of the cost-effective-
ness model iterations favored laser ablation. In a two-way comparison between foam 
sclerotherapy and surgery, 54.5% of the model iterations favored surgery.
CONCLUSIONS
In a randomized trial of treatments for varicose veins, disease-specific quality of life 
5 years after treatment was better after laser ablation or surgery than after foam 
sclerotherapy. The majority of the probabilistic cost-effectiveness model iterations 
favored laser ablation at a willingness-to-pay ratio of £20,000 ($28,433) per QALY. 
(Funded by the National Institute for Health Research; CLASS Current Controlled 
Trials number, ISRCTN51995477.)
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Minimally invasive treatment op-tions such as endovenous laser ablation therapy and ultrasound-guided foam 
sclerotherapy are now recommended alternatives 
to surgery for the treatment of varicose veins.1-9 
Medium-term follow-up studies suggest that laser 
ablation, foam sclerotherapy, and surgery result in 
equivalent recurrence rates and quality of life at 
2 years and 3 years after treatment.10-12 At 5 years, 
quality of life appears to be similar among those 
who underwent laser ablation and those who 
underwent surgery,10,13-15 but limited comparative 
data are available on persons who underwent 
foam sclerotherapy.16 There is also a paucity of 
data on clinical recurrence rates, which has led 
to uncertainty regarding the cost-effectiveness of 
these treatments.
We performed the Comparison of Laser, Sur-
gery, and Foam Sclerotherapy (CLASS) trial, a 
large, multicenter, randomized, comparative-
effectiveness trial, to assess quality of life and 
cost-effectiveness associated with treatment for 
varicose veins at 6 months and 5 years after 
treatment.9,17,18 Here, we present the 5-year pri-
mary outcomes of the CLASS trial.
Me thods
Study Oversight
This study was conducted according to the pro-
tocol, available with the full text of this article 
at NEJM.org.9 Approval of the trial for all sites 
was obtained from the Scotland A Research Eth-
ics Committee and the Medicines and Healthcare 
Products Regulatory Authority. Aberdeen Univer-
sity was responsible for initiation, management, 
and financial oversight of the research. The trial 
was overseen by a trial steering committee and 
an independent data and safety monitoring com-
mittee. Data analysis was performed by statisti-
cians at the Centre for Healthcare Randomized 
Trials, University of Aberdeen. The project man-
agement group (see the Supplementary Appen-
dix, available at NEJM.org) assumes responsibil-
ity for the accuracy and completeness of the data 
and the fidelity of the trial to the protocol.
Patients
Patients who were eligible for treatment of vari-
cose veins were recruited at 11 vascular surgery 
departments in the United Kingdom from No-
vember 2008 through October 2012. Inclusion 
criteria were an age of 18 years or older, the 
presence of primary symptomatic varicose veins 
greater than 3 mm in diameter in one or both 
legs, and reflux of the great saphenous or small 
saphenous veins of more than 1 second as mea-
sured by duplex ultrasonography. In participants 
with varicose veins in both legs, the more severely 
affected leg was designated as the study leg. 
Exclusion criteria were current deep-vein throm-
bosis, acute superficial-vein thrombosis, and ad-
ditional anatomical and participant factors (listed 
in Table S1 in the Supplementary Appendix). 
Written informed consent was obtained from all 
participants.
Randomization and Study Treatment
We compared foam sclerotherapy, laser ablation 
(with subsequent foam sclerotherapy for residual 
varicosities, if necessary), and surgery. Partici-
pants underwent randomization with the use of 
a computer-generated randomization system, with 
balanced assignment to all treatment options 
available at each investigating center within two 
strata — stratum A, which included eight hospi-
tals offering all three treatment options; and 
stratum B, which included three hospitals offer-
ing treatment only with foam sclerotherapy and 
surgery. Randomization was performed with the 
use of a minimization algorithm that included 
center, age (<50 years or ≥50 years), sex, reflux 
in the great or the small saphenous veins, and 
varicose veins in one or both legs. Because of the 
nature of the treatment, participants and asses-
sors were aware of the group assignments.
The laser ablation, foam sclerotherapy, and 
surgical treatment methods have been described 
previously (Table S2 in the Supplementary Ap-
pendix).9 Laser ablation was performed, with the 
patient under local anesthesia, in a treatment 
room in the case of 90.5% of legs treated and in 
an operating theater in the case of 9.5%. Surgery 
was performed while the patient was under gen-
eral anesthesia in an ambulatory care setting. In 
patients with varicose veins in both legs, both 
legs were treated with the same method when 
possible.
Follow-up and Outcome Measures
Five years after treatment, all participants were 
invited to attend a 5-year follow-up clinic appoint-
ment. If they did not attend, they were mailed 
participant questionnaires followed by two mailed 
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reminders. The medical records of all partici-
pants were reviewed by a trial nurse to deter-
mine the timing and nature of any treatment 
the participants received after the initial pro-
cedure.
The primary outcome measures at 5 years 
were participant-reported disease-specific quality 
of life measured with the Aberdeen Varicose Vein 
Questionnaire (AVVQ)19-22; participant-reported 
generic quality of life measured with the Euro-
Qol EQ-5D (EQ-5D) questionnaire23 and the 
Medical Outcomes Study 36-Item Short-Form 
Health Survey (SF-36)24 (physical-component and 
mental-component scores); and 5-year model-
based cost-effectiveness calculated as cost per 
quality-adjusted life-year (QALY) gained. The 
AVVQ consists of 12 questions and a set of man-
nequin legs on which participants are asked to 
draw their veins. AVVQ scores range from 0 to 
100, with lower scores indicating a better qual-
ity of life. The EQ-5D has five dimensions, and 
scores range from −0.594 to 1.000, with higher 
scores indicating a better quality of life. The 
SF-36 consists of eight domains and yields two 
summary scores (the physical component score 
and the mental component score), each of which 
ranges from 0 to 100, with higher scores indicat-
ing greater well-being. Our previously constructed 
Markov model was updated with observed rates 
of recurrence and further treatment, and the 
cost and utility impact (i.e., the effect of recur-
rence and further treatment on the cost and ef-
fects outcomes) of these events were derived from 
the 5-year analysis of individual patient data.17,18 
(Additional details on the Markov model and on 
all scales and scores included in this article are 
provided in Fig. S1 and Table S3 in the Supple-
mentary Appendix.)
Secondary outcomes were quality of life mea-
sured with the EQ-5D visual-analogue scale (VAS; 
scores range from 0 to 100, with higher scores 
indicating better health) and the SF-36 domain 
scores; trial-based incremental cost-effectiveness, 
assessed with the use of data on costs and QALYs 
for individual patients; clinical success as mea-
sured by the presence of varicose veins assessed 
by the participant and nurse using a VAS that 
ranged from 0 (no varicose veins) to 10 (the 
worst varicose veins the patient can imagine) 
and the Venous Clinical Severity Score (a score 
consisting of nine categories relating to symp-
toms or signs of venous disease and one cate-
gory relating to the use of compression; scores 
range from 0 [no venous disease] to 30 [most 
severe venous disease]); additional procedures 
for treatment of varicose veins and the associ-
ated costs; and participant satisfaction and will-
ingness to repeat and recommend the treatment. 
In addition, the effect of the treatments on 
truncal-vein ablation, as assessed by duplex ultra-
sonography, was determined in a subgroup of 
participants.
Statistical Analysis
We performed intention-to-treat analyses for the 
following prespecified comparisons: a compari-
son of foam sclerotherapy with surgery using data 
from participants in strata A and B, a compari-
son of laser ablation with surgery using data 
from patients in stratum A, and a comparison 
of laser ablation with foam sclerotherapy using 
data from patients in stratum A. The principal 
analyses of the trial were performed when all 
participants had completed a 5-year follow-up 
and were conducted according to a prespecified 
statistical plan (available with the protocol at 
NEJM.org), with the use of Stata software, ver-
sion 14 (StataCorp). The study database was 
locked on August 15, 2017, before the analyses 
were performed.
To determine the treatment effect size, we 
compared the groups using general linear models 
with adjustments for the minimization covari-
ates and, when possible, with adjustments for 
baseline scores on the AVVQ, EQ-5D, SF-36, and 
Venous Clinical Severity Score. Mixed models 
with a compound-symmetry covariance matrix 
and with the center fitted as a random effect 
were used to analyze the continuous outcomes. 
All the available data were used to estimate ef-
fect sizes and interactions, and any missing data 
were assumed to be missing at random. Details 
of available interval quality-of-life data are includ-
ed in Table S4 in the Supplementary Appendix. 
Sensitivity analyses were performed to compare 
the demographic characteristics of patients who 
completed the 5-year follow-up with those of 
patients who did not complete the 5-year follow-
up.25 As an additional sensitivity analysis, multi-
ple imputation with chained equations was per-
formed for the primary quality-of-life outcomes 
at 5 years. We analyzed truncal-vein ablation rates 
and treatment satisfaction using ordinal logistic 
regression.
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Details of the original power calculation were 
published previously.9 The initial planned sam-
ple size was 1015 patients but was later revised 
to 779 on the basis of results of a review by the 
data and safety monitoring committee. The ob-
jective was to have at least 90% power to detect 
a difference of 0.25 standard deviation in the 
AVVQ score for the comparison of foam sclero-
therapy with surgery at 6 months; this difference 
was considered to be clinically significant. The 
sample size calculations accounted for an esti-
mated 30% loss to follow-up at 5 years. A statis-
tical significance level of 5% was adjusted to 
account for multiple comparisons (P<0.0033) for 
primary outcomes. Confidence intervals have 
not been adjusted for multiplicity, and therefore 
inferences drawn from these intervals may not 
be reproducible.
Both the model-based and trial-based eco-
nomic analyses included a three-way comparison 
of foam sclerotherapy, surgery, and laser abla-
tion with participant data from stratum A and a 
two-way comparison (foam sclerotherapy vs. 
surgery) with data from Strata A and B. The 
statistical methods for the economic analyses 
are provided in Tables S5 and S6 and the text in 
the Supplementary Appendix.
R esult s
Patients and Treatment
We recruited 798 participants, of whom 595 
(75%) completed the participant questionnaires 
at 5 years, including questionnaires assessing 
quality of life, presence of varicose veins, satisfac-
tion with treatment, and further treatment they 
had received (Fig. 1). The baseline demographic 
and clinical data are shown in Table 1. A sensi-
tivity analysis showed that participants who did 
not complete the 5-year follow-up questionnaires 
were younger than those who did complete the 
questionnaires (mean age, 44.5 years vs. 51.0 
years; P<0.001) (Table S7 in the Supplementary 
Appendix).
Data on 766 participants (96%) were extract-
ed from case notes. In total, 467 participants 
(59%) attended a clinic visit at which a nurse 
assessed the secondary outcomes of Venous 
Clinical Severity Score and extent of varicose 
veins; 389 participants (49%) underwent duplex 
ultrasonography, which was performed at seven 
centers.
Primary Outcomes
Table 2 summarizes results for the four primary 
quality-of-life outcome measures. All groups 
showed improvement from baseline in quality of 
life. The AVVQ scores in the laser ablation and 
surgery groups were significantly lower (indicat-
ing better quality of life) than the scores in the 
foam sclerotherapy group (effect size for laser 
ablation vs. foam sclerotherapy, −2.86; 95% con-
fidence interval [CI], −4.49 to −1.22; P<0.001; 
and effect size for surgery vs. foam sclerother-
apy, −2.60; 95% CI, −3.99 to −1.22; P<0.001). A 
sensitivity analysis revealed no significant dif-
ferences in the baseline or 6-month AVVQ scores 
between patients who did not complete the 
5-year follow-up and those who completed the 
5-year follow-up. The other quality-of-life mea-
sures did not differ significantly among the 
treatment groups. Sensitivity analyses of the 
quality-of-life measures with the use of multiple 
imputation with chained equations revealed simi-
lar results. (Also see Tables S8 and S9 in the 
Supplementary Appendix.)
The updated Markov model results are shown 
in Table 3. In the three-way model-based cost-
effectiveness analysis, laser ablation cost £460 
($654 in U.S. dollars) more than foam sclero-
therapy and generated a nonsignificant gain in 
QALYs (0.113), for an incremental cost-effective-
ness ratio of £4,064 ($5,778) per QALY gained. 
Surgery cost £289 ($411) more than laser abla-
tion and generated marginally fewer QALYs; as a 
result, from a cost-effectiveness standpoint, laser 
ablation was deemed to be superior to surgery. 
At a threshold willingness-to-pay ratio of £20,000 
($28,433) per QALY, 77.2% of the probabilistic 
model iterations favored laser ablation (Fig. 2). 
Figure S2 in the Supplementary Appendix shows 
the uncertainty surrounding the joint incremen-
tal costs and effects for the three-way comparison.
In the two-way comparison of foam sclero-
therapy with surgery, surgery cost an additional 
£737 ($1,048) per patient, for a mean QALY gain 
of 0.042, resulting in an incremental cost-effec-
tiveness ratio of £17,554 ($24,956) (Table 3). 
Figure S3 in the Supplementary Appendix shows 
the uncertainty surrounding the joint incremen-
tal costs and effects for the two-way compari-
son. At the willingness-to-pay threshold of 
£20,000 ($28,433) per QALY, 54.5% of the model 
iterations favored surgery (Fig. S4 in the Supple-
mentary Appendix).
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Figure 1. Screening, Randomization, and Follow-up.
A total of 13 participants (1.6%) were excluded after randomization because they had veins greater than 15 mm in diameter (5 partici-
pants), recurrent varicose veins (3 participants), or coexisting conditions or absence of reflux (5 participants). Participants who were 
 assigned to treatment with laser ablation or foam sclerotherapy had the option of retreatment with foam sclerotherapy for any residual 
varicosities at or after the 6-week follow-up assessment. One site performed concurrent phlebectomies at the time of laser therapy.
7 col
474
798 Underwent randomization
6592 Patients were assessed for eligibility
2847 Were ineligible
376 Had unknown eligibility status
3369 Patients were eligible
2571 Declined to participate
5 Were excluded after
randomization
6 Were excluded after
randomization
2 Were excluded after
randomization
212 Were assigned to undergo
laser ablation
294 Were assigned to undergo surgery
292 Were assigned to undergo
foam sclerotherapy 
210 Were included in the trial
203 (97%) Received assigned treatment
286 Were included in the trial
265 (93%) Received assigned treatment
289 Were included in the trial
252 (87%) Received assigned treatment
6-Wk Follow-up6-Wk Follow-up 6-Wk Follow-up
193 (92%) Underwent clinical
assessment
186 (89%) Completed questionnaire
6 (3%) Were withdrawn
265 (93%) Underwent clinical
assessment
247 (86%) Completed questionnaire
12 (4%) Were withdrawn
251 (87%) Underwent clinical
assessment
237 (82%) Completed questionnaire
29 (10%) Were withdrawn
6-Mo Follow-up
236 (82%) Underwent clinical
assessment
214 (74%) Completed questionnaire
33 (11%) Were withdrawn
6-Mo Follow-up
251 (88%) Underwent clinical
assessment
238 (83%) Completed questionnaire
16 (6%) Were withdrawn
6-Mo Follow-up
183 (87%) Underwent clinical
assessment
175 (83%) Completed questionnaire
9 (4%) Were withdrawn
5-Yr Follow-up5-Yr Follow-up
162 (76%) Completed primary
outcome questionnaire
209 (99%) Had medical note review
127 (60%) Underwent clinical 
assessment
24 (11%) Were withdrawn
3 (1%) Died
219 (75%) Completed primary
outcome questionnaire
279 (96%) Had medical note review
170 (58%) Underwent clinical 
assessment
32 (11%) Were withdrawn
5 (2%) Died
5-Yr Follow-up
214 (73%) Completed primary
outcome questionnaire
278 (95%) Had medical note review
170 (58%) Underwent clinical 
assessment
47 (16%) Were withdrawn
2 (1%) Died
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Secondary Outcomes
There were no major differences between groups 
in SF-36 subscales or EQ-5D VAS scores. With 
regard to patient satisfaction, the majority of par-
ticipants were willing to repeat the same treat-
ment and to recommend the treatment they had 
received to a friend (Tables S10 and S11 in the 
Supplementary Appendix).
At 5 years, 58% of the patients who had under-
gone laser ablation, 54% who had undergone 
surgery, and 47% who had undergone foam 
sclerotherapy reported having no varicose veins 
(odds ratio for foam sclerotherapy vs. laser abla-
tion, 0.59; 95% CI, 0.41 to 0.85). Overall, 11% of 
the patients in the laser ablation group, 14% 
in the foam sclerotherapy group, and 7% in the 
surgery group had further treatment.
The mean (±SD) extent of varicose veins as 
Characteristic
Laser Ablation 
Group 
(N = 210)
Foam Sclerotherapy 
Group 
(N = 286)
Surgery  
Group 
(N = 289)
Age — yr 49.7±14.4 49.0±13.3 49.2±13.7
Female sex — no. (%) 120 (57.1) 162 (56.6) 163 (56.4)
Body-mass index†
Mean 27.0±4.6 27.1±4.4 27.7±4.7
Data missing — no. (%) 14 (6.7) 17 (5.9) 28 (9.7)
Involvement of one leg — no. (%) 153 (72.9) 215 (75.2) 196 (67.8)
Deep-vein thrombosis — no. (%)
History of deep-vein thrombosis 6 (2.9) 4 (1.4) 9 (3.1)
Data missing 4 (1.9) 2 (0.7) 3 (1.0)
Saphenous vein involvement
Great saphenous vein — no. (%) 182 (86.7) 232 (81.1) 239 (82.7)
Widest diameter — mm‡ 9.1±3.1 8.4±2.7 8.7±2.8
Reflux above the knee only — no. (%)§ 151 (96.2) 169 (93.9) 180 (98.4)
Reflux above and below the knee — no. (%)§¶ 6 (3.8) 11 (6.1) 3 (1.6)
Small saphenous vein — no. (%) 14 (6.7) 21 (7.3) 21 (7.3)
Widest diameter — mm 7.1±1.7 7.6±2.2 7.7±3.3
Deep-vein reflux — no. (%)
Presence of deep-vein reflux‖ 28 (13.3) 47 (16.4) 25 (8.7)
Data missing 6 (2.9) 6 (2.1) 8 (2.8)
CEAP classification — no. (%)**
C2, varicose veins >3 mm in diameter 113 (54.1) 169 (59.1) 147 (51.2)
C3, edema 28 (13.4) 35 (12.2) 39 (13.6)
C4, skin and subcutaneous changes 56 (26.8) 74 (25.9) 90 (31.4)
C5 or C6, skin changes with healed or active venous 
ulcer
12 (5.7) 8 (2.8) 11 (3.8)
Data missing 1 (0.5) 2 (0.7)
*  Plus–minus values are means ±SD. CEAP denotes clinical, etiologic, anatomical, and pathophysiological.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  P = 0.008 for the comparison between the laser ablation group and the foam sclerotherapy group.
§  The percentages are based on the total numbers of participants with great saphenous vein involvement.
¶  P = 0.02 for the comparison between the foam sclerotherapy group and the surgery group.
‖  P = 0.006 for the comparison between the foam sclerotherapy group and the surgery group.
**  The percentages for the individual classifications are based on the total number of participants in each treatment 
group minus those for whom data are missing.
Table 1. Baseline Characteristics of the Study Participants.*
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determined by the participant-reported VAS score 
was 2.6±2.2 with laser ablation, 3.2±2.5 with 
foam sclerotherapy, and 2.4±2.3 with surgery 
(effect size for laser ablation vs. foam sclero-
therapy, −0.79; 95% CI, −1.24 to −0.34; and for 
surgery vs. foam sclerotherapy, −0.74; 95% CI, 
−1.12 to −0.36). Similar scores were noted for 
the nurse-reported VAS scores. Venous Clinical 
Severity Score assessments were better at 5 years 
than at baseline in all three groups. The rates of 
complete success with respect to truncal-vein 
ablation at 5 years were 64.0% with laser abla-
tion, 33.3% with foam sclerotherapy, and 75.9% 
with surgery. (Additional details on effect sizes 
are provided in Tables S12 and S13 in the Sup-
plementary Appendix.)
The individual patient cost and utility data for 
the three-way analysis and two-way analysis, per-
formed according to the intention-to-treat prin-
ciple, are summarized in Tables S14 and S15, 
respectively, in the Supplementary Appendix. In 
the adjusted trial-data–based cost-effectiveness 
analysis, treatment with laser ablation had the 
highest chance (71.6%) of being cost-effective in 
the three-way comparison, at a ceiling willing-
ness-to-pay ratio of £20,000 ($28,433) per QALY 
gained. In the two-way comparison, the incre-
mental cost-effectiveness ratio for surgery as com-
pared with foam sclerotherapy was below the 
willingness-to-pay threshold of £20,000 ($28,433) 
per QALY gained in 83.3% of the bootstrapped 
samples (Table S16 in the Supplementary Ap-
pendix). There were no significant differences in 
QALYs among the treatment methods.
Discussion
In this large, multicenter trial comparing sur-
gery, laser ablation, and foam sclerotherapy for 
the treatment of primary varicose veins, quality 
of life was better at 5 years than at baseline in 
all groups. Five years after treatment, there were 
significant differences between the treatments 
with respect to disease-specific quality of life. 
The AVVQ scores were better among participants 
treated with laser ablation or surgery than 
among those treated with foam sclerotherapy, 
with effect sizes of 2.86 and 2.60, respectively. 
Quality of life was similar in the laser ablation 
and surgery groups. The 5-year cost-effective 
analyses were generally in keeping with our pre-
viously reported model-based estimates — name-* 
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Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
ly, laser ablation performed under a local anes-
thetic in a treatment-room setting had a 77% 
probability of being cost-effective up to a will-
ingness-to-pay maximum of £20,000 ($28,433). 
There was considerable uncertainty in the two-
way cost-effective analysis comparing foam sclero-
therapy with surgery.
One previous, smaller study showed that at 
5 years after treatment there was greater im-
provement in disease-specific quality of life (a 
secondary outcome) among patients treated with 
laser ablation than among those treated with 
foam sclerotherapy, but no difference in disease-
specific quality of life was observed between 
patients who underwent foam sclerotherapy and 
those who underwent surgery.16 The differences 
in quality of life observed in our study are likely 
to relate to the fact that the presence and extent 
of varicose veins at 5 years were less in the laser 
ablation and surgery groups than in the foam 
sclerotherapy group, because disease-specific 
quality of life has previously been shown to be 
worse among patients who have recurrent disease 
than among those who do not.26 At 5 years, the 
presence of varicose veins after laser ablation as 
reported by the participants in this study was 
similar to the clinician-reported presence of vari-
cose veins in two other studies14,15; in contrast, 
marginally fewer patients in this study who under-
went surgery reported varicose veins at 5 years 
than the clinician-reported percentage (54%) in 
the two other studies.14,15 The observed percent-
age of patients with successful truncal-vein abla-
tion was higher among patients treated with laser 
ablation and surgery than among those treated 
with foam sclerotherapy, a finding that is consis-
tent with results in other studies.16,27,28 It should 
be noted that patient satisfaction was high, 
which may partly explain the lower reinterven-
tion rates in this trial than in other trials.16,28 
Whether restrictions on treatment for varicose 
veins within the National Health Service influ-
enced retreatment rates is unclear.
The primary Markov model and the trial-data–
based analysis both showed laser ablation to be 
favored on the basis of cost-effectiveness. De-
spite a higher-than-predicted presence of vari-
cose veins at 5 years (42% after laser ablation, vs. 
29% predicted; 46% after surgery, vs. 37% pre-
dicted; and 53% after foam sclerotherapy, vs. 
40% predicted) and a lower reintervention rate, 
our results are generally in keeping with our T
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previously reported model-based estimates de-
rived from an existing network meta-analysis of 
trials.17,18 This previous meta-analysis included 
eight trials, the majority of which had less than 
3 years of follow-up.29 Other Markov models 
have also shown laser ablation to have the high-
est chance of being cost-effective,30,31 whereas one 
has favored foam sclerotherapy.32 The model-
based two-way comparison indicated that sur-
gery cost considerably more than foam sclero-
therapy and generated a small, nonsignificant 
QALY gain. The magnitude of the QALY gain 
was sensitive to the analysis method, in that it 
was larger in the two-way trial-data–based analy-
sis than in the three-way analysis, although it 
was still nonsignificant in the two-way analysis. 
The larger QALY gain in the two-way analysis as 
compared with the three-way analysis is partly 
explained by more unrelated deaths occurring in 
the foam sclerotherapy group during follow-up.
Limitations of our study include the lack of 
a sham procedure and the fact that patients and 
assessors were aware of the treatments. There was 
a substantial amount of missing data at 5 years, 
although the response rate with respect to 
participant-reported outcomes was higher than 
anticipated.
In summary, this large, multicenter trial com-
paring the clinical effectiveness of laser ablation, 
foam sclerotherapy, and surgery for the treatment 
of varicose veins showed that in all three groups, 
quality of life 5 years after treatment was im-
proved from baseline. However, there were clin-
ically important between-group differences in 
disease-specific quality of life that favored laser 
ablation and surgery over foam sclerotherapy. 
Laser ablation was similar to surgery with respect 
to quality of life and of the three treatments had 
the highest chance of being cost-effective.
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Figure 2. Markov-Model–Based Analysis of the Cost-Effectiveness  
of the Three Treatments at 5 Years.
Costs were converted to U.S. dollars with the use of the Organization for 
Economic Cooperation and Development (OECD) purchasing power parities 
for 2017 (£0.703402 equivalent to $1). With this conversion, the equivalent 
value for £10,000 is $14,217; for £20,000 is $28,433; for £30,000 is $42,650; 
for £40,000 is $56,867; and for £50,000 is $71,083. More information about 
purchasing power parities is available at www . oecd . org/ sdd/ purchasing 
powerparitiespppsdata . htm.
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